CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment

Carlos Eduardo Silvado
Vera Cristina Terra
Carlos Alexandre Twardowschy

Abstract: Phenytoin (PHT) is an antiepileptic drug widely used in the treatment of focal epilepsy and status epilepticus, and effective in controlling focal seizures with and without tonic–clonic generalization and status epilepticus. The metabolism of PHT is carried out by two oxidative cytochrome P450 enzymes CYP2C9 and CYP2C19; 90% of this metabolism is done by CYP2C9 and the remaining 10% by CYP2C19. Genetic polymorphism of CYP2C9 may reduce the metabolism of PHT by 25–50% in patients with variants *2 and *3 compared to those with wild-type variant *1. The frequency distribution of CYP2C9 polymorphism alleles in patients with epilepsy around the world ranges from 4.5 to 13.6%, being less frequent in African-Americans and Asians. PHT has a narrow therapeutic range and a nonlinear pharmacokinetic profile; hence, its poor metabolism has significant clinical implications as it causes more frequent and more serious adverse effects requiring discontinuation of treatment, even if it had been effective. There is evidence that polymorphisms of CYP2C9 and the use of PHT are associated with an increase in the frequency of some side effects, such as cerebellar atrophy, gingival hypertrophy or acute cutaneous reactions. The presence of HLA-B*15:02 and CYP2C9 *2 or *3 in the same patient increases the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis; hence, PHT should not be prescribed in these patients. In patients with CYP2C9 *1/*2 or *1/*3 alleles (intermediate metabolizers), the usual PHT maintenance dose (5–10 mg/kg/day) must be reduced by 25%, and in those with CYP2C9 *2/*2, *2/*3 or *3/*3 alleles (poor metabolizers), the dose must be reduced by 50%. It is controversial whether CYP2C9 genotyping should be done before starting PHT treatment. In this paper, we aim to review the influence of CYP2C9 polymorphism on the metabolism of PHT and the clinical implications of poor metabolism in the treatment of epilepsies.

Keywords: phenytoin, antiepileptics, CYP2C9, cytochrome P450, epilepsy, polymorphisms, adverse effects

Introduction
Phenytoin (PHT) was introduced about 80 years ago for use in epilepsy and still remains one of the most prescribed antiepileptic drugs (AEDs) to control partial seizures, either with or without secondary generalization, and for the treatment of status epilepticus. It is available worldwide for use in outpatient setting, as well as in almost all emergency services.

The main mechanism of action of PHT is the selective blockage of neuronal voltage-dependent sodium channels in their inactive state. Fosphenytoin is the prodrug (a water-soluble phosphate ester) of PHT, which is hydrolyzed to PHT by phosphatases.
The metabolism of PHT is rather complex, and 95% of PHT is eliminated by biotransformation through a number of pathways. The main step is the conversion to (R,S)-5-(p-hydroxyphenyl)-5-phenyl-hydantoin (p-HPPH), leading to the formation of a reactive arene oxide intermediate, which could play a role in the pathogenesis of some of the idiosyncratic adverse reactions, including serious cutaneous reactions, hepatotoxicity and teratogenicity. Secondary hydroxylated metabolites include m-HPPH and a dihydrodiol, which is further metabolized to a glucuronide and to a catechol derivative. Approximately 98% of circulating p-HPPH is in levo isomor “S”. Overall, p-HPPH accounts for 67–88% and dihydrodiol for 7–11% of the human urinary metabolites of PHT.6

PHT exhibits a nonlinear pharmacokinetic profile, due to saturation of the oxidation route by two hepatic oxidative cytochrome P450 enzymes (CYPs) CYP2C9 and CYP2C19.7–9 This metabolism is reduced in persons with genetic polymorphisms and also by the interaction of these systems with other drugs.8

PHT is metabolized by both CYP2C9 and CYP2C19, which are responsible for the conversion of inactive PHT to its main metabolite, p-HPPH; CYP2C9 is responsible for 90% of this metabolism, whereas CYP2C19 metabolizes the remaining 10%.10

Genetic polymorphism of CYP2C9 may reduce the metabolism of PHT by 25–50% in patients who have the genetic variants *2 and *3, as compared to those with variant *1 (normal metabolizers), named the “wild types” or the “extensive metabolizers”.11 PHT has a nonlinear pharmacokinetic profile,11 and its therapeutic range is rather narrow and may be even more pronounced in patients who have a genetic polymorphism that may cause poor metabolism which might have significant clinical implications as it causes more frequent and more serious adverse effects requiring discontinuation of treatment, even if it had been effective in seizure control.

In this review, we discuss the influence of genetic polymorphism of the CYP2C9 on the metabolism of PHT and the clinical implications of poor metabolism.

**Pharmacogenetics of CYP2C9**

Pharmacogenetic is the study of the relationship between variations in a single gene and the action of drugs, and that these genetic variations help to explain the reason for either treatment failure or toxic effects of the administration of various pharmaceutical compounds. Knowledge of these variations may help to predict which patients are at an increased risk of toxicity and identify those who are most likely to achieve the desired drug therapeutic effect.12

Additionally, response variability depends on differences in metabolism, usually caused by genetic polymorphisms. Genetic polymorphisms occurring as a result of single-nucleotide exchange in the DNA sequence are more frequent, whereas others occurring as a result of either insertions or deletions of multiple-nucleotide sequences are less frequent. Currently, it is quite clear that genetic polymorphisms play a key role in the variability in pharmacokinetics and pharmacodynamics of AEDs, and can affect their efficacy, tolerability, safety and duration of action.13–17

Elimination of drugs usually occurs by either hepatic (metabolism) or renal (excretion) routes. Metabolism is the most important route both quantitatively and qualitatively, and can be further divided into Phase I, in which oxidative reactions are catalyzed by many CYPs, and Phase II, in which conjugation reactions occur as a result of glucuronidation.18

The CYPs are encoded by 57 human genes, whose products take part in the oxidative drug metabolism of approximately 90% of all clinically prescribed drugs, and genetic polymorphisms of CYPs are responsible for the interindividual variability in the pharmacokinetics of AEDs. CYP3A4 is the most important hepatic CYP and accounts for more than a third of all hepatic CYPs. For many AEDs (PHT, phenobarbital, carbamazepine, ethosuximide, felbamate, oxcarbazepine, eslicarbazepine, clobazam), oxidation by CYPs (3A4, 2C9, 2C19) is the main metabolism route.18–22 Therefore, changes in this enzyme system have important implications in the management of epileptic patients, particularly side effects and drug interactions.23–25

Depending on DNA variability, drug metabolism may be altered in various locations with potential changes in absorption, distribution, transport, metabolism, elimination and sites of action. The AEDs are not only mere substrates but can also induce or inhibit genes involved in their own and other drugs’ metabolism.26

The action of CYP2C9 is induced by rifampicin, increasing the clearance of drugs eliminated by CYP2C9, such as losartan, PHT, tolbutamide, warfarin and others, by almost 50%. Inhibition of CYP2C9 metabolism, reducing the clearance of drugs eliminated by CYP2C9, could be caused by antidepressants (fluoxetine, fluvoxamine, imipramine, sertraline, trazodone, viloxazine), antimicrobials (chloramphenicol, fluconazole, isoniazid, miconazole, sulfaphenazole) and other drugs (allopurinol, amiodarone, cimetidine, dextropropoxyphene, diltiazem, disulfiram, doxifluridine, 5-fluorouracil, omeprazole, phenylbutazone, sulfinpyrazone, tacrolimus,
CYP2C9 polymorphisms in epilepsy

The gene CYP2C9 and its variants

CYP2C9 is one of the most abundant CYPs in the human liver (~20% of total hepatic CYP content), responsible for the metabolism of approximately 15% of all clinical drugs (>100 drugs) and is highly polymorphic, with >35 genetic variations being reported.

It is an important member of the CYP2C subfamily, having been mapped to chromosome 10q24.2 and is a highly variable gene; nucleotide sequencing has already identified almost 60 alleles. However, only three alleles, namely CYP2C9 *1 (the wild-type allele, as it is the most common in the population), CYP2C9 *2 and CYP2C9 *3 (both with reduced enzyme activities), are often identified in ethnic population studies.

The CYP2C9 *2 variant has a C>T transition at position 432 of exon 3 encoding arginine, causing an exchange of cysteine at position 144 (Arg144Cys) of CYP2C9 protein, while the analysis of the variant CYP2C9 *3 demonstrated A>T1077 transversion in exon 7 which encodes an amino acid exchanging isoleucine to leucine at position 359 (Ile359Leu).

Ethnicity should be taken into account when pharmacogenetic information is used to make a clinical decision, as the frequency of CYP2C9 alleles varies among populations according to the race and ethnic background. A large number of studies have demonstrated a marked variation in the frequency distribution of CYP2C9 alleles around the world, with the wild-type allele frequency ranging from 76.5 to 96.7%. This difference occurs among white and black Africans, white and black Americans, Indian ethnic groups, Japanese, Middle East and North African populations, Swedish population, and Brazilian population. These mutations are less frequent in Asians and African-Americans.

Table 1 summarizes the frequency of CYP2C9 *2 and CYP2C9 *3 alleles in various ethnic groups around the world.

Other variants are rare and have been reported in different ethnic groups; the CYP2C9 *4 is an extremely rare variant identified in Japanese epileptic patients, the CYP2C9 *5

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of cases</th>
<th>Country population</th>
<th>*2 frequency (%)</th>
<th>*3 frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soga et al[29]</td>
<td>56</td>
<td>Japanese</td>
<td>0</td>
<td>5.4</td>
</tr>
<tr>
<td>Nasu et al[84]</td>
<td>218</td>
<td>Japanese</td>
<td>0</td>
<td>2.1</td>
</tr>
<tr>
<td>Wang et al[85]</td>
<td>115</td>
<td>Han Chinese</td>
<td>0</td>
<td>1.7</td>
</tr>
<tr>
<td>Sullivan-Klose et al[30]</td>
<td>100</td>
<td>Caucasian Americans</td>
<td>3.0</td>
<td>2.0</td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>African-Americans</td>
<td>1.0</td>
<td>0.5</td>
</tr>
<tr>
<td></td>
<td>98</td>
<td>Taiwanese</td>
<td>0</td>
<td>1.7</td>
</tr>
<tr>
<td>Stubbins et al[34]</td>
<td>100</td>
<td>Caucasian British</td>
<td>12.5</td>
<td>8.5</td>
</tr>
<tr>
<td>Hardt et al[82]</td>
<td>247</td>
<td>Egyptians</td>
<td>12.0</td>
<td>6.0</td>
</tr>
<tr>
<td>Ayacioglu et al[37]</td>
<td>499</td>
<td>Turks</td>
<td>10.6</td>
<td>10.0</td>
</tr>
<tr>
<td>Brockmoller et al[35]</td>
<td>174</td>
<td>Germans</td>
<td>13</td>
<td>8.1</td>
</tr>
<tr>
<td>Yasar et al[38]</td>
<td>430</td>
<td>Swedish</td>
<td>10.7</td>
<td>7.4</td>
</tr>
<tr>
<td>Vianna-Jorge et al[42]</td>
<td>331</td>
<td>Brazilians</td>
<td>8.6</td>
<td>6.5</td>
</tr>
<tr>
<td>Jose et al[44]</td>
<td>346</td>
<td>Indians (South)</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td>Scordo et al[39]</td>
<td>157</td>
<td>Italians</td>
<td>11.2</td>
<td>9.2</td>
</tr>
<tr>
<td>Kimura et al[36]</td>
<td>140</td>
<td>Japanese</td>
<td>0</td>
<td>3.6</td>
</tr>
<tr>
<td>Yoon et al[47]</td>
<td>574</td>
<td>Koreans</td>
<td>0</td>
<td>1.1</td>
</tr>
<tr>
<td>Gaedigk et al[41]</td>
<td>153</td>
<td>Canadians</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Sanchez-Diz et al[46]</td>
<td>1076</td>
<td>Spanish and Italians</td>
<td>12.5–16.5</td>
<td>7.1–8.5</td>
</tr>
<tr>
<td>Scott et al[45]</td>
<td>250</td>
<td>US Ashkenazi Jews</td>
<td>14</td>
<td>8.6</td>
</tr>
</tbody>
</table>
Phenotype metabolic changes comparing both CYP2C9 wild-type and mutant variants

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Methods</th>
<th>Results of mutant variants versus wild-type variant</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosemary et al</td>
<td>27</td>
<td>300 mg PHT, 4 h after intake</td>
<td>Double ↑ BL-PHT in the presence of mutant alleles</td>
<td>0.01</td>
</tr>
<tr>
<td>Kerb et al</td>
<td>96</td>
<td>300 mg PHT, 12 h after intake</td>
<td>1 mutant allele = ↑ 31% BL-PHT</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2 mutant alleles = ↑ 52% BL-PHT</td>
<td></td>
</tr>
<tr>
<td>Aynacioglu et al</td>
<td>101</td>
<td>300 mg PHT, 12 h after intake</td>
<td>*1/2 = ↑ 32% BL-PHT</td>
<td>0.009</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>*1/3 = ↑ 35% BL-PHT</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>*2/2 = ↑ 58% BL-PHT</td>
<td>0.02</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>*3/3 = ↑ 42% BL-PHT</td>
<td>Not calculated</td>
</tr>
<tr>
<td>Soga et al</td>
<td>28</td>
<td>Chronic use, 2 h after intake</td>
<td>*1/3 = ↑ 58% ratio C/D</td>
<td>0.01</td>
</tr>
<tr>
<td>Hung et al</td>
<td>169</td>
<td>Chronic use, average daily PHT dose of 293.64 ± 75.20 mg/kg/day</td>
<td>*1/1 CYP2C9 + C19 (mutant) = ↓ 20% C1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>*1/3 CYP2C9 + C19 (mutant) = ↓ 50% C1</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Ozkaynakci et al</td>
<td>102</td>
<td>Chronic use, average daily PHT dose of 4.13 ± 1.07 mg/kg/day</td>
<td>Mean BL-PHT: Group CYP2C9 *1/3 + CYP2C19 *2/3 = 27.95 ± 1.85 µg/mL (highest)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mean BL-PHT: Group CYP2C9 *1/1 + CYP2C19 *1/1 = 7.43 ± 0.73 µg/mL (lowest)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: N, number of patients; PHT, phenytoin; BL-PHT, blood level of phenytoin; C/D, serum phenytoin concentration/dose of phenytoin; CI, clearance of phenytoin.

Adverse effects of PHT

Phenytoin could cause a variety of idiosyncratic or dose-related effects, which can be significantly more common in patients who have the CYP2C9 *2 and CYP2C9 *3 variants. Conversely, a recent study of epileptic children in Northern India showed that patients with alleles *2 and *3 had a significant increase in serum PHT, but without a higher incidence of side effects.

Reversible cosmetic changes, such as hirsutism and coarse facial features, could be problematic, especially in female adolescents. Gingival hypertrophy is another frequent problem, although the mechanisms underlying its development are still debatable. Inflammation resulting from plaque, increase in sulfated glycosaminoglycans, population differences in gingival immunoglobulin content and fibroblast count, epithelial growth factors and pharmacokinetics of tissue-binding factors have all been reported as possible causative agents. Individuals carrying alleles *3 and *2 showed no higher gingival hyperplasia than those carrying the wild-type alleles, suggesting that this symptom should be due to other factors.

The risk of craniofacial abnormalities in children after fetal exposure to PHT had been reported; however, this was not associated with the maternal CYP2C9 genotype, but rather with the presence of polymorphisms of the rare maternal alleles EPHX1, Y113H and H139R, which compromises the metabolism of arene oxide intermediate to inactive

Table 2 Allele frequency of CYP2C9 *2 and CYP2C9 *3 in patients with epilepsy

<table>
<thead>
<tr>
<th>Study</th>
<th>Number of cases</th>
<th>Country population</th>
<th>*2 frequency (%)</th>
<th>*3 frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hashimoto et al</td>
<td>17</td>
<td>Japanese</td>
<td>0</td>
<td>11.8</td>
</tr>
<tr>
<td>Odani et al</td>
<td>44</td>
<td>Japanese</td>
<td>0</td>
<td>13.6</td>
</tr>
<tr>
<td>Soga et al</td>
<td>28</td>
<td>Japanese</td>
<td>0</td>
<td>10.7</td>
</tr>
<tr>
<td>Twardowschy et al</td>
<td>100</td>
<td>Brazilians</td>
<td>9</td>
<td>7.0</td>
</tr>
<tr>
<td>Chaudhary et al</td>
<td>89</td>
<td>Indians</td>
<td>4.5</td>
<td>10.1</td>
</tr>
</tbody>
</table>
compounds. Variation in EPHX1 activity could affect fetal exposure to the reactive oxide intermediate.62

PHT could induce acute cutaneous reactions such as maculopapular exanthema or severe manifestations such as Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or drug reactions with eosinophilia and systemic symptoms, which occur primarily in the first eight weeks of treatment.59,63–65 A study showed that Korean epileptic patients with genotype CYP2C9 *1/*3 developed more maculopapular rash associated with PHT when compared to controls with or without exposure to PHT (an increase in relative risk of about 170-fold).59 Similarly, Thai epileptic patients with the CYP2C9 *3 genotype had significantly more SJS and TEN due to PHT than patients with the wild-type allele (23% versus 6.5%), but without significant differences in the HLA-B*15:02.66 It is not clear if either the role of CYP2C9 alleles in non-Asian ethnic groups or slow dose titration of PHT itself is responsible for reducing the risk of cutaneous acute reactions as compared to those occurring with lamotrigine.6

The neurotoxic side effects of PHT (drowsiness, dysarthria, tremor, ataxia, and cognitive impairment) are very likely to occur when plasma levels exceed 20 mg/mL.18,50 The presence of polymorphism of CYP2C9 could increase the incidence and severity of neurotoxic side effects. The presence of a null allele for the CYP2C9 enzyme can result in the most severe PHT intoxication.66

Studies show that prolonged use of PHT correlates directly with the development of cerebellar atrophy (CA).56,67 It is suspected that acute exposure to high doses of PHT may also be associated with the development of this complication,68–70 and CA can be induced experimentally in animals by the administration of PHT leading to loss of Purkinje cells and glial damage to the granular layer.71

The incidence of CA in patients using PHT, either acutely or chronically,70 can be as high as 50% of patients.73 Older patients in particular are at a higher risk, as CA was observed in this group more frequently, indicating that either advanced age itself or a longer duration of the epilepsy could also be an important factor in the pathogenesis of cerebellar degeneration.57

Administration of PHT in newborn mice can result in a reduction in both cerebellar weight and size.74 Also, changes in white matter distribution and neuronal cell counts in both the Purkinje cells and granular layers have been reported in rats after exposure to this drug.75 Twardowschy et al have recently demonstrated that the presence of variant alleles *2 and *3 may be associated with a smaller cerebellar white matter and volume in patients with epilepsy, treated with PHT for at least 1 year.76

### Clinical implications of use of PHT in patients with CYP2C9 polymorphisms

PHT is a highly protein-bound drug (90%), which can cause significant dose-dependent toxicity to the central nervous system. Because of its narrow therapeutic range and nonlinear pharmacokinetic profile, the therapeutic and toxic effects of PHT show a relatively good relationship with its serum concentration.77

Table 3 shows that the frequency of mutant alleles *2 and *3 in patients with epilepsy is 4.5–13.6%. These patients have reduced PHT metabolism, thus being at an increased risk of severe or frequent side effects during the use of PHT at a dosage of 5–10 mg/kg PO. Risks are even higher and more relevant in the emergency management of status epilepticus, when the recommended dose of PHT is a IV bolus of 20 mg/kg, especially if patients have hypalbuminemia or if patients are in intensive care unit.67 In patients with CYP2C9 *1/*2 or *1/*3 alleles (intermediate metabolizers), the PHT maintenance dose must be reduced by 25%, and in those with CYP2C9 *2/*2, *2/*3 or *3/*3 alleles (poor metabolizers), the dose must be reduced by 50%.55,58,79,80

Patients positive for HLA-B*15:02 could also be at an increased risk of PHT-induced SJS/TEN, particularly if they have CYP2C9 *2 or *3 genotypes. The Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing and the US Food and Drug Administration proposed that neither PHT nor fosphenytoin should be used in these patients.81

It is also very important to consider the interactions of PHT with other drugs.

PHT meets all the pharmacogenomic prerequisites necessary for change in drug effect to be considered clinically important, as proposed by MacKenzie and Hall:82

1. The effect of the polymorphism on the total active drug moiety should be considerable.
2. There should be a clear concentration-versus-response relation.
3. There should be severe concentration-dependent adverse effects.
4. There should be a narrow therapeutic index.

Future use of pharmacogenomics, particularly for the intensive care unit patients, will be more helpful, given our current inability to predict either the efficacy or the occurrence of unwanted adverse effects of drugs in a population at high risk of being administered large doses of drugs, usually
as an IV bolus, more prone to severe adverse effects and with little physiological reserve to compensate them. 62

**Conclusion**

PHT is a very effective drug to treat epilepsy and one of the best options for treating status epilepticus, but its dosages should be individualized to reduce the risk of side effects that could justify its withdrawal, even when effective. The presence of CYP2C9 polymorphism reduces 25–50% of the metabolism of PHT, increasing the risk of side effects with the use of usual (5–10 mg/kg) PHT daily dose.

It is still controversial whether CYP2C9 genotyping should be performed on a regular basis before starting PHT treatment. We need prospective well-controlled studies to prove that individualizing antiepileptic doses in any given patient, either avoiding or reducing the risk of serious side effects, is superior to clinical observation and blood level assessments. There are many other confounding factors that could influence the metabolism and incidence of side effects associated with PHT use, such as age, body weight, pregnancy, drug interactions and so on, in addition to CYP2C9 polymorphisms. 6,80,83

As soon as genetic testing for detection of polymorphisms becomes more readily available and cost-effective, we will be able to estimate the metabolism rates and drug interactions, before the prescription and administration of a drug, thus providing a real personalized medicine.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


